
Article

Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States

Juan Pablo Alderuccio ¹, Jorge A. Florindez ², Isildinha M. Reis ^{3,4}, Wei Zhao ⁴ and Izidore S. Lossos ^{1,5,*}

¹ Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; jalderuccio@med.miami.edu

² Department of Medicine, Division of Hospital Medicine, University of Miami Miller School of Medicine, Miami, FL, USA; jorgeflorindez@med.miami.edu

³ Department of Public Health Science; ireis@med.miami.edu

⁴ Sylvester Biostatistics and Bioinformatics Core Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; wzhao2@med.miami.edu

⁵ Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

* Correspondence: ilossos@med.miami.edu; Tel.: +305-243-4785; Fax: +305-243-4787

Supplementary

Table S1. Univariable and multivariable analyses for OS and LSS in stage I EMZL who were treated with surgery and radiation.


		Overall survival (OS) (174 deaths)				Lymphoma-specific survival (LSS) (40 deaths from lymphoma and 134 deaths from other cause as competing risk)			
		Univariable		Multivariable		Univariable		Multivariable	
Variable	Category	HR (95%CI)	P	HR (95%CI)	P	SHR (95%CI)	P	SHR (95%CI)	P
Age	<60	Reference		Reference		Reference		Reference	
	≥60	7.10 (4.65, 10.9)	<.001	7.82 (5.09, 12.0)	<.001	5.62 (2.36, 13.4)	<.001	5.32 (2.23, 12.7)	<.001
Sex	Female	Reference		Reference		Reference		Reference	
	Male	1.02 (0.75, 1.38)	0.899	1.27 (0.92, 1.75)	0.149	0.72 (0.37, 1.39)	0.329	0.92 (0.46, 1.83)	0.816
Race	Non-Hispanic White	Reference		Reference		Reference		Reference	
	Black	1.29 (0.77, 2.17)	0.332	1.77 (1.03, 3.02)	0.038	1.69 (0.67, 4.29)	0.270	1.76 (0.69, 4.47)	0.235
	Others	0.68 (0.43, 1.10)	0.115	0.72 (0.45, 1.17)	0.186	0.49 (0.15, 1.62)	0.241	0.62 (0.19, 2.08)	0.442
Ethnicity	Non-Hispanic	Reference		Reference		Reference		Reference	
	Hispanic	0.98 (0.61, 1.56)	0.926	1.13 (0.70, 1.83)	0.610	1.08 (0.43, 2.71)	0.869	1.38 (0.52, 3.66)	0.518
Primary location	Gastric	Reference		Reference		Reference		Reference	
	Skin	0.42 (0.20, 0.89)	0.024	0.48 (0.23, 1.01)	0.054	0.15 (0.04, 0.63)	0.009	0.23 (0.05, 1.03)	0.054
	Ocular adnexa	0.68 (0.36, 1.30)	0.248	0.72 (0.38, 1.39)	0.332	0.30 (0.11, 0.85)	0.023	0.38 (0.13, 1.08)	0.070
	GI non-gastric	0.22 (0.03, 1.67)	0.142	0.15 (0.02, 1.20)	0.074	0.50 (0.07, 3.83)	0.505	0.52 (0.07, 3.97)	0.529
	Salivary glands	0.96 (0.50, 1.84)	0.901	1.02 (0.53, 1.97)	0.959	0.36 (0.12, 1.06)	0.063	0.44 (0.15, 1.26)	0.126
	Lungs	0.42 (0.12, 1.53)	0.190	0.47 (0.13, 1.71)	0.252	NE		NE	
	Breasts	0.98 (0.42, 2.31)	0.964	1.17 (0.49, 2.79)	0.731	0.80 (0.23, 2.86)	0.737	1.08 (0.29, 3.96)	0.910
	Oral	0.71 (0.27, 1.82)	0.472	0.46 (0.18, 1.21)	0.117	0.24 (0.03, 2.03)	0.192	0.24 (0.03, 1.83)	0.167
	Thyroid	0.34 (0.12, 0.91)	0.031	0.31 (0.11, 0.85)	0.023	0.28 (0.05, 1.48)	0.134	0.36 (0.07, 2.00)	0.244
	Others	0.64 (0.26, 1.59)	0.335	0.53 (0.21, 1.33)	0.176	0.72 (0.20, 2.60)	0.613	0.70 (0.20, 2.46)	0.576
DLBCL transformation	No	Reference		Reference		Reference		Reference	

		Overall survival (OS) (174 deaths)				Lymphoma-specific survival (LSS) (40 deaths from lymphoma and 134 deaths from other cause as competing risk)			
Variable	Category	Univariable		Multivariable		Univariable		Multivariable	
		HR (95%CI)	P	HR (95%CI)	P	SHR (95%CI)	P	SHR (95%CI)	P
	Yes	0.98 (0.31, 3.08)	0.979	0.57 (0.18, 1.80)	0.337	4.93 (1.74, 14.0)	0.003	2.80 (1.13, 6.95)	0.027

HR: hazard ratio. SHR: subdistribution hazard ratio. 95% CI: 95% confidence interval. HGT: High grade transformation.

Table 2. Non lymphoma-related causes of death.

	N	%
Cardiovascular diseases	499	32.0
Respiratory diseases	192	12.3
Gastrointestinal-Liver diseases	107	6.9
Infectious diseases	98	6.3
Cerebrovascular disease	83	5.3
Alzheimer disease	65	4.2
Accidents-Adverse effects	46	3.3
Renal diseases	37	2.4
Other malignancies	19	1.2
Other causes	412	26.4






Figure 1. Overall survival (OS) by treatment strategy within EMZL primary location subgroups: Gastric (A), Skin (B), ocular adnexa (C), salivary gland (D), and lung (E). Note: When there was a significant effect of treatment modality on OS (overall $p < 0.05$), plots display estimated hazard ratios and corresponding p-values from Cox regression univariable models.